Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sacituzumab Tirumotecan + Tagitanlimab in Early-stage High-risk ER+/HER2- Breast Cancer
NCT07109284Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in breast cancer, sponsored by West China Hospital of Sichuan University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07109284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109284.